

References

1. Hanahan, D. and R.A. Weinberg, *Hallmarks of cancer: the next generation*. Cell, 2011. **144**(5): p. 646-74.
2. Stratton, M.R., P.J. Campbell, and P.A. Futreal, *The cancer genome*. Nature, 2009. **458**(7239): p. 719-24.
3. Cheng, N., et al., *Transforming growth factor-beta signaling-deficient fibroblasts enhance hepatocyte growth factor signaling in mammary carcinoma cells to promote scattering and invasion*. Mol Cancer Res, 2008. **6**(10): p. 1521-33.
4. Amit, I., et al., *A module of negative feedback regulators defines growth factor signaling*. Nat Genet, 2007. **39**(4): p. 503-12.
5. Jiang, B.H. and L.Z. Liu, *PI3K/PTEN signaling in angiogenesis and tumorigenesis*. Adv Cancer Res, 2009. **102**: p. 19-65.
6. Collado, M. and M. Serrano, *Senescence in tumours: evidence from mice and humans*. Nat Rev Cancer, 2010. **10**(1): p. 51-7.
7. Ghebranious, N. and L.A. Donehower, *Mouse models in tumor suppression*. Oncogene, 1998. **17**(25): p. 3385-400.
8. Blasco, M.A., *Telomeres and human disease: ageing, cancer and beyond*. Nat Rev Genet, 2005. **6**(8): p. 611-22.
9. Ferrara, N., *Pathways mediating VEGF-independent tumor angiogenesis*. Cytokine Growth Factor Rev, 2010. **21**(1): p. 21-6.
10. Teng, M.W., et al., *Immune-mediated dormancy: an equilibrium with cancer*. J Leukoc Biol, 2008. **84**(4): p. 988-93.
11. Nelson, B.H., *The impact of T-cell immunity on ovarian cancer outcomes*. Immunol Rev, 2008. **222**: p. 101-16.
12. Sunshine, J. and J.M. Taube, *PD-1/PD-L1 inhibitors*. Curr Opin Pharmacol, 2015. **23**: p. 32-8.
13. Syn, N.L., et al., *De-novo and acquired resistance to immune checkpoint targeting*. Lancet Oncol, 2017. **18**(12): p. e731-e741.
14. Negrini, S., V.G. Gorgoulis, and T.D. Halazonetis, *Genomic instability--an evolving hallmark of cancer*. Nat Rev Mol Cell Biol, 2010. **11**(3): p. 220-8.
15. Korkola, J. and J.W. Gray, *Breast cancer genomes--form and function*. Curr Opin Genet Dev, 2010. **20**(1): p. 4-14.
16. Kinzler, K.W. and B. Vogelstein, *Cancer-susceptibility genes. Gatekeepers and caretakers*. Nature, 1997. **386**(6627): p. 761, 763.
17. Visvader, J.E. and G.J. Lindeman, *Cancer stem cells in solid tumours: accumulating evidence and unresolved questions*. Nat Rev Cancer, 2008. **8**(10): p. 755-68.
18. Caren, H., et al., *Glioblastoma Stem Cells Respond to Differentiation Cues but Fail to Undergo Commitment and Terminal Cell-Cycle Arrest*. Stem Cell Reports, 2015. **5**(5): p. 829-842.
19. Singh, A. and J. Settleman, *EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer*. Oncogene, 2010. **29**(34): p. 4741-51.
20. Kurzwelly, D., U. Herrlinger, and M. Simon, *Seizures in patients with low-grade gliomas--incidence, pathogenesis, surgical management, and pharmacotherapy*. Adv Tech Stand Neurosurg, 2010. **35**: p. 81-111.
21. Noorani, I. and N. Sanai, *Surgical Management of Incidental Gliomas*. Neurosurg Clin N Am, 2017. **28**(3): p. 397-406.

22. Mandonnet, E., et al., *Silent diffuse low-grade glioma: toward screening and preventive treatment?* *Cancer*, 2014. **120**(12): p. 1758-62.
23. Pallud, J., et al., *The silent phase of diffuse low-grade gliomas. Is it when we missed the action?* *Acta Neurochir (Wien)*, 2013. **155**(12): p. 2237-42.
24. Stupp, R., et al., *Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.* *N Engl J Med*, 2005. **352**(10): p. 987-96.
25. Perry, J.R., et al., *Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma.* *N Engl J Med*, 2017. **376**(11): p. 1027-1037.
26. Gilbert, M.R., et al., *A randomized trial of bevacizumab for newly diagnosed glioblastoma.* *N Engl J Med*, 2014. **370**(8): p. 699-708.
27. Brennan, C.W., et al., *The somatic genomic landscape of glioblastoma.* *Cell*, 2013. **155**(2): p. 462-77.
28. Cancer Genome Atlas Research, N., *Comprehensive genomic characterization defines human glioblastoma genes and core pathways.* *Nature*, 2008. **455**(7216): p. 1061-8.
29. Holland, E.C., et al., *Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice.* *Nat Genet*, 2000. **25**(1): p. 55-7.
30. Parsons, D.W., et al., *An integrated genomic analysis of human glioblastoma multiforme.* *Science*, 2008. **321**(5897): p. 1807-12.
31. Sasaki, M., et al., *IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics.* *Nature*, 2012. **488**(7413): p. 656-9.
32. Sasaki, M., et al., *D-2-hydroxyglutarate produced by mutant IDH1 perturbs collagen maturation and basement membrane function.* *Genes Dev*, 2012. **26**(18): p. 2038-49.
33. Bardella, C., et al., *Expression of Idh1(R132H) in the Murine Subventricular Zone Stem Cell Niche Recapitulates Features of Early Gliomagenesis.* *Cancer Cell*, 2016. **30**(4): p. 578-594.
34. Eckel-Passow, J.E., et al., *Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors.* *N Engl J Med*, 2015. **372**(26): p. 2499-508.
35. Tobin, M.K., et al., *Intramedullary spinal cord tumors: a review of current and future treatment strategies.* *Neurosurg Focus*, 2015. **39**(2): p. E14.
36. Jallo, G.I., D. Freed, and F. Epstein, *Intramedullary spinal cord tumors in children.* *Childs Nerv Syst*, 2003. **19**(9): p. 641-9.
37. Raco, A., et al., *Long-term follow-up of intramedullary spinal cord tumors: a series of 202 cases.* *Neurosurgery*, 2005. **56**(5): p. 972-81; discussion 972-81.
38. Chamberlain, M.C. and T.L. Tredway, *Adult primary intradural spinal cord tumors: a review.* *Curr Neurol Neurosci Rep*, 2011. **11**(3): p. 320-8.
39. Chamberlain, M.C., *Temozolomide for recurrent low-grade spinal cord gliomas in adults.* *Cancer*, 2008. **113**(5): p. 1019-24.
40. De Witt Hamer, P.C., et al., *The genomic profile of human malignant glioma is altered early in primary cell culture and preserved in spheroids.* *Oncogene*, 2008. **27**(14): p. 2091-6.
41. Mouse Genome Sequencing, C., et al., *Initial sequencing and comparative analysis of the mouse genome.* *Nature*, 2002. **420**(6915): p. 520-62.
42. Trotman, L.C., et al., *Pten dose dictates cancer progression in the prostate.* *PLoS Biol*, 2003. **1**(3): p. E59.
43. Olive, K.P., et al., *Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome.* *Cell*, 2004. **119**(6): p. 847-60.
44. Silver, L., *Mouse Genetics - Concepts and Applications.* . Oxford University Press, 1995.
45. Uren, A.G., et al., *Retroviral insertional mutagenesis: past, present and future.* *Oncogene*, 2005. **24**(52): p. 7656-72.

46. Mikkers, H., et al., *High-throughput retroviral tagging to identify components of specific signaling pathways in cancer*. Nat Genet, 2002. **32**(1): p. 153-9.
47. Mikkers, H., J. Allen, and A. Berns, *Proviral activation of the tumor suppressor E2a contributes to T cell lymphomagenesis in EmuMyc transgenic mice*. Oncogene, 2002. **21**(43): p. 6559-66.
48. Ivics, Z., et al., *Molecular reconstruction of Sleeping Beauty, a Tc1-like transposon from fish, and its transposition in human cells*. Cell, 1997. **91**(4): p. 501-10.
49. Cui, Z., et al., *Structure-function analysis of the inverted terminal repeats of the sleeping beauty transposon*. J Mol Biol, 2002. **318**(5): p. 1221-35.
50. Geurts, A.M., et al., *Gene transfer into genomes of human cells by the sleeping beauty transposon system*. Mol Ther, 2003. **8**(1): p. 108-17.
51. Mates, L., et al., *Molecular evolution of a novel hyperactive Sleeping Beauty transposase enables robust stable gene transfer in vertebrates*. Nat Genet, 2009. **41**(6): p. 753-61.
52. Collier, L.S., et al., *Cancer gene discovery in solid tumours using transposon-based somatic mutagenesis in the mouse*. Nature, 2005. **436**(7048): p. 272-6.
53. Takeda, H., et al., *Transposon mutagenesis identifies genes and evolutionary forces driving gastrointestinal tract tumor progression*. Nat Genet, 2015. **47**(2): p. 142-50.
54. Kas, S.M., et al., *Insertional mutagenesis identifies drivers of a novel oncogenic pathway in invasive lobular breast carcinoma*. Nat Genet, 2017. **49**(8): p. 1219-1230.
55. Bard-Chapeau, E.A., et al., *Transposon mutagenesis identifies genes driving hepatocellular carcinoma in a chronic hepatitis B mouse model*. Nat Genet, 2014. **46**(1): p. 24-32.
56. Wu, X., et al., *Clonal selection drives genetic divergence of metastatic medulloblastoma*. Nature, 2012. **482**(7386): p. 529-33.
57. Rahrman, E.P., et al., *Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis*. Nat Genet, 2013. **45**(7): p. 756-66.
58. Moriarity, B.S., et al., *A Sleeping Beauty forward genetic screen identifies new genes and pathways driving osteosarcoma development and metastasis*. Nat Genet, 2015. **47**(6): p. 615-24.
59. Chen, L., et al., *Transposon insertional mutagenesis in mice identifies human breast cancer susceptibility genes and signatures for stratification*. Proc Natl Acad Sci U S A, 2017. **114**(11): p. E2215-E2224.
60. Mann, M.B., et al., *Transposon mutagenesis identifies genetic drivers of Braf(V600E) melanoma*. Nat Genet, 2015. **47**(5): p. 486-95.
61. Dupuy, A.J., et al., *Mammalian mutagenesis using a highly mobile somatic Sleeping Beauty transposon system*. Nature, 2005. **436**(7048): p. 221-6.
62. Mann, K.M., et al., *Sleeping Beauty mutagenesis reveals cooperating mutations and pathways in pancreatic adenocarcinoma*. Proc Natl Acad Sci U S A, 2012. **109**(16): p. 5934-41.
63. Rahrman, E.P., et al., *Identification of PDE4D as a proliferation promoting factor in prostate cancer using a Sleeping Beauty transposon-based somatic mutagenesis screen*. Cancer Res, 2009. **69**(10): p. 4388-97.
64. Bender, A.M., et al., *Sleeping beauty-mediated somatic mutagenesis implicates CSF1 in the formation of high-grade astrocytomas*. Cancer Res, 2010. **70**(9): p. 3557-65.
65. Collier, L.S., et al., *Whole-body sleeping beauty mutagenesis can cause penetrant leukemia/lymphoma and rare high-grade glioma without associated embryonic lethality*. Cancer Res, 2009. **69**(21): p. 8429-37.
66. Koso, H., et al., *Transposon mutagenesis identifies genes that transform neural stem cells into glioma-initiating cells*. Proc Natl Acad Sci U S A, 2012. **109**(44): p. E2998-3007.

67. de la Rosa, J., et al., *A single-copy Sleeping Beauty transposon mutagenesis screen identifies new PTEN-cooperating tumor suppressor genes*. Nat Genet, 2017. **49**(5): p. 730-741.
68. Ding, S., et al., *Efficient transposition of the piggyBac (PB) transposon in mammalian cells and mice*. Cell, 2005. **122**(3): p. 473-83.
69. Rad, R., et al., *PiggyBac transposon mutagenesis: a tool for cancer gene discovery in mice*. Science, 2010. **330**(6007): p. 1104-7.
70. Rad, R., et al., *A conditional piggyBac transposition system for genetic screening in mice identifies oncogenic networks in pancreatic cancer*. Nat Genet, 2015. **47**(1): p. 47-56.
71. Urnov, F.D., et al., *Genome editing with engineered zinc finger nucleases*. Nat Rev Genet, 2010. **11**(9): p. 636-46.
72. Miller, J.C., et al., *A TALE nuclease architecture for efficient genome editing*. Nat Biotechnol, 2011. **29**(2): p. 143-8.
73. Ishino, Y., et al., *Nucleotide sequence of the iap gene, responsible for alkaline phosphatase isozyme conversion in Escherichia coli, and identification of the gene product*. J Bacteriol, 1987. **169**(12): p. 5429-33.
74. Mojica, F.J., et al., *Biological significance of a family of regularly spaced repeats in the genomes of Archaea, Bacteria and mitochondria*. Mol Microbiol, 2000. **36**(1): p. 244-6.
75. Barrangou, R., et al., *CRISPR provides acquired resistance against viruses in prokaryotes*. Science, 2007. **315**(5819): p. 1709-12.
76. Jinek, M., et al., *A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity*. Science, 2012. **337**(6096): p. 816-21.
77. Cong, L., et al., *Multiplex genome engineering using CRISPR/Cas systems*. Science, 2013. **339**(6121): p. 819-23.
78. Fu, Y., et al., *High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells*. Nat Biotechnol, 2013. **31**(9): p. 822-6.
79. Wang, T., et al., *Genetic screens in human cells using the CRISPR-Cas9 system*. Science, 2014. **343**(6166): p. 80-4.
80. Shalem, O., et al., *Genome-scale CRISPR-Cas9 knockout screening in human cells*. Science, 2014. **343**(6166): p. 84-87.
81. Koike-Yusa, H., et al., *Genome-wide recessive genetic screening in mammalian cells with a lentiviral CRISPR-guide RNA library*. Nat Biotechnol, 2014. **32**(3): p. 267-73.
82. Gilbert, L.A., et al., *Genome-Scale CRISPR-Mediated Control of Gene Repression and Activation*. Cell, 2014. **159**(3): p. 647-61.
83. Konermann, S., et al., *Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex*. Nature, 2015. **517**(7536): p. 583-8.
84. Golic, K.G. and S. Lindquist, *The FLP recombinase of yeast catalyzes site-specific recombination in the Drosophila genome*. Cell, 1989. **59**(3): p. 499-509.
85. Friedel, R.H., et al., *Generating conditional knockout mice*. Methods Mol Biol, 2011. **693**: p. 205-31.
86. Fisher, G.H., et al., *Development of a flexible and specific gene delivery system for production of murine tumor models*. Oncogene, 1999. **18**(38): p. 5253-60.
87. Tronche, F., et al., *Disruption of the glucocorticoid receptor gene in the nervous system results in reduced anxiety*. Nat Genet, 1999. **23**(1): p. 99-103.
88. Dubois, N.C., et al., *Nestin-Cre transgenic mouse line Nes-Cre1 mediates highly efficient Cre/loxP mediated recombination in the nervous system, kidney, and somite-derived tissues*. Genesis, 2006. **44**(8): p. 355-60.

89. Liang, H., S. Hippenmeyer, and H.T. Ghashghaei, *A Nestin-cre transgenic mouse is insufficient for recombination in early embryonic neural progenitors*. Biol Open, 2012. **1**(12): p. 1200-3.
90. Zhuo, L., et al., *hGFAP-cre transgenic mice for manipulation of glial and neuronal function in vivo*. Genesis, 2001. **31**(2): p. 85-94.
91. Downward, J., et al., *Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences*. Nature, 1984. **307**(5951): p. 521-7.
92. Holland, E.C., et al., *A constitutively active epidermal growth factor receptor cooperates with disruption of G1 cell-cycle arrest pathways to induce glioma-like lesions in mice*. Genes Dev, 1998. **12**(23): p. 3675-85.
93. Ceccarelli, M., et al., *Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma*. Cell, 2016. **164**(3): p. 550-63.
94. Zheng, H., et al., *p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation*. Nature, 2008. **455**(7216): p. 1129-33.
95. Alcantara Llaguno, S.R., et al., *Adult Lineage-Restricted CNS Progenitors Specify Distinct Glioblastoma Subtypes*. Cancer Cell, 2015. **28**(4): p. 429-440.
96. Zhu, H., et al., *Oncogenic EGFR signaling cooperates with loss of tumor suppressor gene functions in gliomagenesis*. Proc Natl Acad Sci U S A, 2009. **106**(8): p. 2712-6.
97. Jacques, T.S., et al., *Combinations of genetic mutations in the adult neural stem cell compartment determine brain tumour phenotypes*. EMBO J, 2010. **29**(1): p. 222-35.
98. Bachoo, R.M., et al., *Epidermal growth factor receptor and Ink4a/Arf: convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis*. Cancer Cell, 2002. **1**(3): p. 269-77.
99. Friedmann-Morvinski, D., et al., *Dedifferentiation of neurons and astrocytes by oncogenes can induce gliomas in mice*. Science, 2012. **338**(6110): p. 1080-4.
100. Doetsch, F., et al., *EGF converts transit-amplifying neurogenic precursors in the adult brain into multipotent stem cells*. Neuron, 2002. **36**(6): p. 1021-34.
101. Liu, C., et al., *Mosaic analysis with double markers reveals tumor cell of origin in glioma*. Cell, 2011. **146**(2): p. 209-21.
102. Lee, J.H., et al., *Human glioblastoma arises from subventricular zone cells with low-level driver mutations*. Nature, 2018.
103. Galvao, R.P., et al., *Transformation of quiescent adult oligodendrocyte precursor cells into malignant glioma through a multistep reactivation process*. Proc Natl Acad Sci U S A, 2014. **111**(40): p. E4214-23.
104. Hitoshi, Y., et al., *Spinal glioma: platelet-derived growth factor B-mediated oncogenesis in the spinal cord*. Cancer Res, 2008. **68**(20): p. 8507-15.
105. Bussolati, G., et al., *Formalin fixation at low temperature better preserves nucleic acid integrity*. PLoS One, 2011. **6**(6): p. e21043.
106. Jentsch, I., et al., *Karyotyping mouse chromosomes by multiplex-FISH (M-FISH)*. Chromosome Res, 2001. **9**(3): p. 211-4.
107. Li, H. and R. Durbin, *Fast and accurate long-read alignment with Burrows-Wheeler transform*. Bioinformatics, 2010. **26**(5): p. 589-95.
108. McKenna, A., et al., *The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data*. Genome Res, 2010. **20**(9): p. 1297-303.
109. Cibulskis, K., et al., *Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples*. Nat Biotechnol, 2013. **31**(3): p. 213-9.

110. Cingolani, P., et al., *A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3*. Fly (Austin), 2012. **6**(2): p. 80-92.
111. Dees, N.D., et al., *MuSiC: identifying mutational significance in cancer genomes*. Genome Res, 2012. **22**(8): p. 1589-98.
112. Li, H., et al., *The Sequence Alignment/Map format and SAMtools*. Bioinformatics, 2009. **25**(16): p. 2078-9.
113. Koboldt, D.C., D.E. Larson, and R.K. Wilson, *Using VarScan 2 for Germline Variant Calling and Somatic Mutation Detection*. Curr Protoc Bioinformatics, 2013. **44**: p. 15 4 1-17.
114. Olshen, A.B., et al., *Circular binary segmentation for the analysis of array-based DNA copy number data*. Biostatistics, 2004. **5**(4): p. 557-72.
115. Mermel, C.H., et al., *GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers*. Genome Biol, 2011. **12**(4): p. R41.
116. Dobin, A., et al., *STAR: ultrafast universal RNA-seq aligner*. Bioinformatics, 2013. **29**(1): p. 15-21.
117. Aken, B.L., et al., *Ensembl 2017*. Nucleic Acids Res, 2017. **45**(D1): p. D635-D642.
118. Love, M.I., W. Huber, and S. Anders, *Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2*. Genome Biol, 2014. **15**(12): p. 550.
119. Subramanian, A., et al., *Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles*. Proc Natl Acad Sci U S A, 2005. **102**(43): p. 15545-50.
120. Mootha, V.K., et al., *PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes*. Nat Genet, 2003. **34**(3): p. 267-73.
121. de Ruyter, J.R., et al., *Identifying transposon insertions and their effects from RNA-sequencing data*. Nucleic Acids Res, 2017. **45**(12): p. 7064-7077.
122. Friedrich, M.J., et al., *Genome-wide transposon screening and quantitative insertion site sequencing for cancer gene discovery in mice*. Nat Protoc, 2017. **12**(2): p. 289-309.
123. de Ridder, J., et al., *Detecting statistically significant common insertion sites in retroviral insertional mutagenesis screens*. PLoS Comput Biol, 2006. **2**(12): p. e166.
124. Yates, A., et al., *Ensembl 2016*. Nucleic Acids Res, 2016. **44**(D1): p. D710-6.
125. Forbes, S.A., et al., *COSMIC: somatic cancer genetics at high-resolution*. Nucleic Acids Res, 2017. **45**(D1): p. D777-D783.
126. Cerami, E., et al., *The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data*. Cancer Discov, 2012. **2**(5): p. 401-4.
127. Wong, A.J., et al., *Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification*. Proc Natl Acad Sci U S A, 1987. **84**(19): p. 6899-903.
128. Klingler, S., et al., *Development of Resistance to EGFR-Targeted Therapy in Malignant Glioma Can Occur through EGFR-Dependent and -Independent Mechanisms*. Cancer Res, 2015. **75**(10): p. 2109-19.
129. Nikolaev, S., et al., *Extrachromosomal driver mutations in glioblastoma and low-grade glioma*. Nat Commun, 2014. **5**: p. 5690.
130. Choe, G., et al., *Analysis of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma patients in vivo*. Cancer Res, 2003. **63**(11): p. 2742-6.
131. Akhavan, D., T.F. Cloughesy, and P.S. Mischel, *mTOR signaling in glioblastoma: lessons learned from bench to bedside*. Neuro Oncol, 2010. **12**(8): p. 882-9.
132. Fan, Q.W., et al., *EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastoma*. Cancer Cell, 2013. **24**(4): p. 438-49.

133. Huang, P.H., et al., *Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma*. Proc Natl Acad Sci U S A, 2007. **104**(31): p. 12867-72.
134. Al-Nedawi, K., et al., *Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells*. Nat Cell Biol, 2008. **10**(5): p. 619-24.
135. Nishikawa, R., et al., *Immunohistochemical analysis of the mutant epidermal growth factor, deltaEGFR, in glioblastoma*. Brain Tumor Pathol, 2004. **21**(2): p. 53-6.
136. Mukasa, A., et al., *Mutant EGFR is required for maintenance of glioma growth in vivo, and its ablation leads to escape from receptor dependence*. Proc Natl Acad Sci U S A, 2010. **107**(6): p. 2616-21.
137. Mitsudomi, T., et al., *Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial*. Lancet Oncol, 2010. **11**(2): p. 121-8.
138. Zhang, Z., et al., *Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer*. Nat Genet, 2012. **44**(8): p. 852-60.
139. Sos, M.L., et al., *PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR*. Cancer Res, 2009. **69**(8): p. 3256-61.
140. Engelman, J.A., et al., *MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling*. Science, 2007. **316**(5827): p. 1039-43.
141. Pao, W., et al., *Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain*. PLoS Med, 2005. **2**(3): p. e73.
142. Mellingerhoff, I.K., et al., *Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors*. N Engl J Med, 2005. **353**(19): p. 2012-24.
143. Peereboom, D.M., et al., *Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme*. J Neurooncol, 2010. **98**(1): p. 93-9.
144. Stommel, J.M., et al., *Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies*. Science, 2007. **318**(5848): p. 287-90.
145. Gedeon, P.C., et al., *Rindopepimut: anti-EGFRvIII peptide vaccine, oncolytic*. Drugs Future, 2013. **38**(3): p. 147-155.
146. Mishima, K., et al., *Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor*. Cancer Res, 2001. **61**(14): p. 5349-54.
147. Mukherjee, B., et al., *EGFRvIII and DNA double-strand break repair: a molecular mechanism for radioresistance in glioblastoma*. Cancer Res, 2009. **69**(10): p. 4252-9.
148. Golding, S.E., et al., *Pro-survival AKT and ERK signaling from EGFR and mutant EGFRvIII enhances DNA double-strand break repair in human glioma cells*. Cancer Biol Ther, 2009. **8**(8): p. 730-8.
149. Nathanson, D.A., et al., *Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA*. Science, 2014. **343**(6166): p. 72-6.
150. Vogt, N., et al., *Molecular structure of double-minute chromosomes bearing amplified copies of the epidermal growth factor receptor gene in gliomas*. Proc Natl Acad Sci U S A, 2004. **101**(31): p. 11368-73.
151. Akhavan, D., et al., *De-repression of PDGFRbeta transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients*. Cancer Discov, 2013. **3**(5): p. 534-47.
152. Clark, P.A., et al., *Activation of multiple ERBB family receptors mediates glioblastoma cancer stem-like cell resistance to EGFR-targeted inhibition*. Neoplasia, 2012. **14**(5): p. 420-8.

153. Schulte, A., et al., *Erlotinib resistance in EGFR-amplified glioblastoma cells is associated with upregulation of EGFRvIII and PI3Kp110delta*. *Neuro Oncol*, 2013. **15**(10): p. 1289-301.
154. Liu, F., et al., *EGFR Mutation Promotes Glioblastoma through Epigenome and Transcription Factor Network Remodeling*. *Mol Cell*, 2015. **60**(2): p. 307-18.
155. Lal, A., et al., *Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasion*. *Cancer Res*, 2002. **62**(12): p. 3335-9.
156. Bai, H., et al., *Integrated genomic characterization of IDH1-mutant glioma malignant progression*. *Nat Genet*, 2016. **48**(1): p. 59-66.
157. Capper, D., et al., *DNA methylation-based classification of central nervous system tumours*. *Nature*, 2018. **555**(7697): p. 469-474.
158. Krex, D., et al., *Long-term survival with glioblastoma multiforme*. *Brain*, 2007. **130**(Pt 10): p. 2596-606.
159. Stichel, D., et al., *Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma*. *Acta Neuropathol*, 2018.
160. Tabori, U., et al., *Epidermal growth factor receptor gene amplification and expression in disseminated pediatric low-grade gliomas*. *J Neurosurg*, 2005. **103**(4 Suppl): p. 357-61.
161. Yan, C., et al., *Glioblastoma multiforme in conus medullaris with intracranial metastasis after postoperative adjuvant therapy*. *Medicine (Baltimore)*, 2017. **96**(13): p. e6500.
162. Zadnik, P.L., et al., *Spinal cord tumours: advances in genetics and their implications for treatment*. *Nat Rev Neurol*, 2013. **9**(5): p. 257-66.
163. Jackson, E.L., et al., *PDGFR alpha-positive B cells are neural stem cells in the adult SVZ that form glioma-like growths in response to increased PDGF signaling*. *Neuron*, 2006. **51**(2): p. 187-99.
164. Chamberlain, M.C., *Leptomeningeal metastases: a review of evaluation and treatment*. *J Neurooncol*, 1998. **37**(3): p. 271-84.
165. Singh, S.K., et al., *Identification of a cancer stem cell in human brain tumors*. *Cancer Res*, 2003. **63**(18): p. 5821-8.
166. Shah, N. and S. Sukumar, *The Hox genes and their roles in oncogenesis*. *Nat Rev Cancer*, 2010. **10**(5): p. 361-71.
167. Verhaak, R.G., et al., *Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1*. *Cancer Cell*, 2010. **17**(1): p. 98-110.
168. Chakravarthi, B.V., et al., *MicroRNA-101 regulated transcriptional modulator SUB1 plays a role in prostate cancer*. *Oncogene*, 2016. **35**(49): p. 6330-6340.
169. Fults, D., et al., *p53 mutation and loss of heterozygosity on chromosomes 17 and 10 during human astrocytoma progression*. *Cancer Res*, 1992. **52**(3): p. 674-9.
170. Sorensen, S.A., J.J. Mulvihill, and A. Nielsen, *Long-term follow-up of von Recklinghausen neurofibromatosis. Survival and malignant neoplasms*. *N Engl J Med*, 1986. **314**(16): p. 1010-5.
171. Lamar, J.M., et al., *The Hippo pathway target, YAP, promotes metastasis through its TEAD-interaction domain*. *Proc Natl Acad Sci U S A*, 2012. **109**(37): p. E2441-50.
172. Lin, L., et al., *The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies*. *Nat Genet*, 2015. **47**(3): p. 250-6.
173. Cancer Genome Atlas Research, N., et al., *Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas*. *N Engl J Med*, 2015. **372**(26): p. 2481-98.
174. Ichimura, K., et al., *IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas*. *Neuro Oncol*, 2009. **11**(4): p. 341-7.

175. Vassiliou, G.S., et al., *Mutant nucleophosmin and cooperating pathways drive leukemia initiation and progression in mice*. Nat Genet, 2011. **43**(5): p. 470-5.
176. Hills, S.A. and J.F. Diffley, *DNA replication and oncogene-induced replicative stress*. Curr Biol, 2014. **24**(10): p. R435-44.
177. Nitta, M., et al., *Targeting EGFR induced oxidative stress by PARP1 inhibition in glioblastoma therapy*. PLoS One, 2010. **5**(5): p. e10767.
178. Zhu, Y., et al., *Inactivation of NF1 in CNS causes increased glial progenitor proliferation and optic glioma formation*. Development, 2005. **132**(24): p. 5577-88.
179. Alcantara Llaguno, S., et al., *Malignant astrocytomas originate from neural stem/progenitor cells in a somatic tumor suppressor mouse model*. Cancer Cell, 2009. **15**(1): p. 45-56.
180. Tuttle, A.H., et al., *Comparing phenotypic variation between inbred and outbred mice*. Nat Methods, 2018. **15**(12): p. 994-996.
181. Bifari, F., et al., *Neurogenic Radial Glia-like Cells in Meninges Migrate and Differentiate into Functionally Integrated Neurons in the Neonatal Cortex*. Cell Stem Cell, 2017. **20**(3): p. 360-373 e7.
182. Francis, J.M., et al., *EGFR variant heterogeneity in glioblastoma resolved through single-nucleus sequencing*. Cancer Discov, 2014. **4**(8): p. 956-71.
183. Patel, D., et al., *Monoclonal antibody cetuximab binds to and down-regulates constitutively activated epidermal growth factor receptor VIII on the cell surface*. Anticancer Res, 2007. **27**(5A): p. 3355-66.
184. Stutz, M.A., et al., *LRIG1 negatively regulates the oncogenic EGF receptor mutant EGFRVIII*. Oncogene, 2008. **27**(43): p. 5741-52.
185. Emlet, D.R., et al., *Targeting a glioblastoma cancer stem-cell population defined by EGF receptor variant III*. Cancer Res, 2014. **74**(4): p. 1238-49.
186. Inda, M.M., et al., *Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma*. Genes Dev, 2010. **24**(16): p. 1731-45.
187. Felsberg, J., et al., *Epidermal Growth Factor Receptor Variant III (EGFRVIII) Positivity in EGFR-Amplified Glioblastomas: Prognostic Role and Comparison between Primary and Recurrent Tumors*. Clin Cancer Res, 2017. **23**(22): p. 6846-6855.
188. Del Vecchio, C.A., et al., *EGFRVIII gene rearrangement is an early event in glioblastoma tumorigenesis and expression defines a hierarchy modulated by epigenetic mechanisms*. Oncogene, 2013. **32**(21): p. 2670-81.
189. Eskilsson, E., et al., *EGFRVIII mutations can emerge as late and heterogenous events in glioblastoma development and promote angiogenesis through Src activation*. Neuro Oncol, 2016. **18**(12): p. 1644-1655.
190. Pandita, A., et al., *Contrasting in vivo and in vitro fates of glioblastoma cell subpopulations with amplified EGFR*. Genes Chromosomes Cancer, 2004. **39**(1): p. 29-36.
191. Reuss, D.E., et al., *Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities*. Acta Neuropathol, 2015. **130**(3): p. 407-17.
192. Lee, M., et al., *Intramedullary spinal cord tumors in neurofibromatosis*. Neurosurgery, 1996. **38**(1): p. 32-7.
193. Horbinski, C., et al., *Association of molecular alterations, including BRAF, with biology and outcome in pilocytic astrocytomas*. Acta Neuropathol, 2010. **119**(5): p. 641-9.
194. Burrell, R.A., et al., *Replication stress links structural and numerical cancer chromosomal instability*. Nature, 2013. **494**(7438): p. 492-496.
195. Campbell, P.J., et al., *The patterns and dynamics of genomic instability in metastatic pancreatic cancer*. Nature, 2010. **467**(7319): p. 1109-13.

196. de Bruin, E.C., et al., *Spatial and temporal diversity in genomic instability processes defines lung cancer evolution*. Science, 2014. **346**(6206): p. 251-6.
197. Gordon, D.J., B. Resio, and D. Pellman, *Causes and consequences of aneuploidy in cancer*. Nat Rev Genet, 2012. **13**(3): p. 189-203.
198. Armenia, J., et al., *The long tail of oncogenic drivers in prostate cancer*. Nat Genet, 2018. **50**(5): p. 645-651.
199. Wang, W., et al., *Chromosomal transposition of PiggyBac in mouse embryonic stem cells*. Proc Natl Acad Sci U S A, 2008. **105**(27): p. 9290-5.
200. Liang, Q., et al., *Chromosomal mobilization and reintegration of Sleeping Beauty and PiggyBac transposons*. Genesis, 2009. **47**(6): p. 404-8.
201. Li, M.A., et al., *The piggyBac transposon displays local and distant reintegration preferences and can cause mutations at noncanonical integration sites*. Mol Cell Biol, 2013. **33**(7): p. 1317-30.
202. Simon, M., et al., *Functional evidence for a role of combined CDKN2A (p16-p14(ARF))/CDKN2B (p15) gene inactivation in malignant gliomas*. Acta Neuropathol, 1999. **98**(5): p. 444-52.
203. Wakioka, T., et al., *Spred is a Sprouty-related suppressor of Ras signalling*. Nature, 2001. **412**(6847): p. 647-51.
204. Sorensen, S.A., J.J. Mulvihill, and A. Nielsen, *On the natural history of von Recklinghausen neurofibromatosis*. Ann N Y Acad Sci, 1986. **486**: p. 30-7.
205. Messiaen, L., et al., *Clinical and mutational spectrum of neurofibromatosis type 1-like syndrome*. JAMA, 2009. **302**(19): p. 2111-8.
206. Wang, S.I., et al., *Somatic mutations of PTEN in glioblastoma multiforme*. Cancer Res, 1997. **57**(19): p. 4183-6.
207. Quayle, S.N., et al., *Somatic mutations of PIK3R1 promote gliomagenesis*. PLoS One, 2012. **7**(11): p. e49466.
208. Ozawa, T., et al., *PDGFRA gene rearrangements are frequent genetic events in PDGFRA-amplified glioblastomas*. Genes Dev, 2010. **24**(19): p. 2205-18.
209. Azim, E., et al., *SOX6 controls dorsal progenitor identity and interneuron diversity during neocortical development*. Nat Neurosci, 2009. **12**(10): p. 1238-47.
210. Uittenbogaard, M. and A. Chiaramello, *Expression of the bHLH transcription factor Tcf12 (ME1) gene is linked to the expansion of precursor cell populations during neurogenesis*. Brain Res Gene Expr Patterns, 2002. **1**(2): p. 115-21.
211. Cohen-Dvashi, H., et al., *Navigator-3, a modulator of cell migration, may act as a suppressor of breast cancer progression*. EMBO Mol Med, 2015. **7**(3): p. 299-314.
212. Takata, M., et al., *The Rad51 paralog Rad51B promotes homologous recombinational repair*. Mol Cell Biol, 2000. **20**(17): p. 6476-82.
213. Zheng, H., et al., *PLAGL2 regulates Wnt signaling to impede differentiation in neural stem cells and gliomas*. Cancer Cell, 2010. **17**(5): p. 497-509.
214. Zhang, N., et al., *FoxM1 promotes beta-catenin nuclear localization and controls Wnt target-gene expression and glioma tumorigenesis*. Cancer Cell, 2011. **20**(4): p. 427-42.
215. Wu, G., et al., *Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas*. Nat Genet, 2012. **44**(3): p. 251-3.
216. Jenkins, R.B., et al., *A cytogenetic study of 53 human gliomas*. Cancer Genet Cytogenet, 1989. **39**(2): p. 253-79.
217. Mertens, F., et al., *Chromosomal imbalance maps of malignant solid tumors: a cytogenetic survey of 3185 neoplasms*. Cancer Res, 1997. **57**(13): p. 2765-80.

218. Saitoh, Y., et al., *Identification of allelic loss on chromosome arm 6p in human astrocytomas by arbitrarily primed polymerase chain reaction*. *Genes Chromosomes Cancer*, 1998. **22**(3): p. 165-70.
219. Fults, D., et al., *Allelotype of human malignant astrocytoma*. *Cancer Res*, 1990. **50**(18): p. 5784-9.
220. Teyssier, J.R. and D. Ferre, *Identification of a clustering of chromosomal breakpoints in the analysis of 203 human primary solid tumor non specific karyotypic rearrangements*. *Anticancer Res*, 1992. **12**(3): p. 997-1004.
221. Ransom, D.T., et al., *Cytogenetic and loss of heterozygosity studies in ependymomas, pilocytic astrocytomas, and oligodendrogliomas*. *Genes Chromosomes Cancer*, 1992. **5**(4): p. 348-56.
222. Thiel, G., et al., *Karyotypes in 90 human gliomas*. *Cancer Genet Cytogenet*, 1992. **58**(2): p. 109-20.
223. Miyakawa, A., et al., *Multiple deleted regions on the long arm of chromosome 6 in astrocytic tumours*. *Br J Cancer*, 2000. **82**(3): p. 543-9.
224. King, H.O., et al., *RAD51 Is a Selective DNA Repair Target to Radiosensitize Glioma Stem Cells*. *Stem Cell Reports*, 2017. **8**(1): p. 125-139.
225. Ishii, N., et al., *Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines*. *Brain Pathol*, 1999. **9**(3): p. 469-79.
226. Pore, N., et al., *PTEN mutation and epidermal growth factor receptor activation regulate vascular endothelial growth factor (VEGF) mRNA expression in human glioblastoma cells by transactivating the proximal VEGF promoter*. *Cancer Res*, 2003. **63**(1): p. 236-41.
227. Ermoian, R.P., et al., *Dysregulation of PTEN and protein kinase B is associated with glioma histology and patient survival*. *Clin Cancer Res*, 2002. **8**(5): p. 1100-6.
228. Smith, J.S., et al., *PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme*. *J Natl Cancer Inst*, 2001. **93**(16): p. 1246-56.
229. Li, J., et al., *PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer*. *Science*, 1997. **275**(5308): p. 1943-7.
230. Kwon, C.H., et al., *Pten haploinsufficiency accelerates formation of high-grade astrocytomas*. *Cancer Res*, 2008. **68**(9): p. 3286-94.
231. Xiao, A., et al., *Astrocyte inactivation of the pRb pathway predisposes mice to malignant astrocytoma development that is accelerated by PTEN mutation*. *Cancer Cell*, 2002. **1**(2): p. 157-68.
232. Chalhoub, N. and S.J. Baker, *PTEN and the PI3-kinase pathway in cancer*. *Annu Rev Pathol*, 2009. **4**: p. 127-50.
233. Hayashi, Y., et al., *Association of EGFR gene amplification and CDKN2 (p16/MTS1) gene deletion in glioblastoma multiforme*. *Brain Pathol*, 1997. **7**(3): p. 871-5.
234. An, Z., et al., *Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies*. *Oncogene*, 2018. **37**(12): p. 1561-1575.
235. Lai, T., et al., *SOX5 controls the sequential generation of distinct corticofugal neuron subtypes*. *Neuron*, 2008. **57**(2): p. 232-47.
236. Lin, D., et al., *ASAP1, a gene at 8q24, is associated with prostate cancer metastasis*. *Cancer Res*, 2008. **68**(11): p. 4352-9.
237. Levine, A.J., J. Momand, and C.A. Finlay, *The p53 tumour suppressor gene*. *Nature*, 1991. **351**(6326): p. 453-6.
238. Hollstein, M., et al., *p53 mutations in human cancers*. *Science*, 1991. **253**(5015): p. 49-53.
239. Malkin, D., et al., *Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms*. *Science*, 1990. **250**(4985): p. 1233-8.
240. Srivastava, S., et al., *Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome*. *Nature*, 1990. **348**(6303): p. 747-9.

241. Ziegler, A., et al., *Mutation hotspots due to sunlight in the p53 gene of nonmelanoma skin cancers*. Proc Natl Acad Sci U S A, 1993. **90**(9): p. 4216-20.
242. Rodrigues, N.R., et al., *p53 mutations in colorectal cancer*. Proc Natl Acad Sci U S A, 1990. **87**(19): p. 7555-9.
243. Momand, J., et al., *The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation*. Cell, 1992. **69**(7): p. 1237-45.
244. Oliner, J.D., et al., *Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53*. Nature, 1993. **362**(6423): p. 857-60.
245. Chen, Z., et al., *Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis*. Nature, 2005. **436**(7051): p. 725-30.
246. Sigal, A. and V. Rotter, *Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome*. Cancer Res, 2000. **60**(24): p. 6788-93.
247. Lang, G.A., et al., *Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome*. Cell, 2004. **119**(6): p. 861-72.
248. Liu, D.P., H. Song, and Y. Xu, *A common gain of function of p53 cancer mutants in inducing genetic instability*. Oncogene, 2010. **29**(7): p. 949-56.
249. Dittmer, D., et al., *Gain of function mutations in p53*. Nat Genet, 1993. **4**(1): p. 42-6.
250. Iggo, R., et al., *Increased expression of mutant forms of p53 oncogene in primary lung cancer*. Lancet, 1990. **335**(8691): p. 675-9.
251. Song, H., M. Hollstein, and Y. Xu, *p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM*. Nat Cell Biol, 2007. **9**(5): p. 573-80.
252. Olivier, M., M. Hollstein, and P. Hainaut, *TP53 mutations in human cancers: origins, consequences, and clinical use*. Cold Spring Harb Perspect Biol, 2010. **2**(1): p. a001008.
253. Biegging, K.T., S.S. Mello, and L.D. Attardi, *Unravelling mechanisms of p53-mediated tumour suppression*. Nat Rev Cancer, 2014. **14**(5): p. 359-70.
254. Adesina, A.M., J. Nalbantoglu, and W.K. Cavenee, *p53 gene mutation and mdm2 gene amplification are uncommon in medulloblastoma*. Cancer Res, 1994. **54**(21): p. 5649-51.
255. Saylor, R.L., 3rd, et al., *Infrequent p53 gene mutations in medulloblastomas*. Cancer Res, 1991. **51**(17): p. 4721-3.
256. Packer, R.J. and G. Vezina, *Management of and prognosis with medulloblastoma: therapy at a crossroads*. Arch Neurol, 2008. **65**(11): p. 1419-24.
257. Thompson, M.C., et al., *Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations*. J Clin Oncol, 2006. **24**(12): p. 1924-31.
258. Kool, M., et al., *Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas*. Acta Neuropathol, 2012. **123**(4): p. 473-84.
259. Gajjar, A.J. and G.W. Robinson, *Medulloblastoma-translating discoveries from the bench to the bedside*. Nat Rev Clin Oncol, 2014. **11**(12): p. 714-22.
260. Jones, D.T., et al., *Dissecting the genomic complexity underlying medulloblastoma*. Nature, 2012. **488**(7409): p. 100-5.
261. Zhukova, N., et al., *Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma*. J Clin Oncol, 2013. **31**(23): p. 2927-35.
262. Hart, M.N. and K.M. Earle, *Primitive neuroectodermal tumors of the brain in children*. Cancer, 1973. **32**(4): p. 890-7.
263. Shingu, T., et al., *Qki deficiency maintains stemness of glioma stem cells in suboptimal environment by downregulating endolysosomal degradation*. Nat Genet, 2017. **49**(1): p. 75-86.

264. Zuckermann, M., et al., *Somatic CRISPR/Cas9-mediated tumour suppressor disruption enables versatile brain tumour modelling*. Nat Commun, 2015. **6**: p. 7391.
265. Chow, R.D., et al., *AAV-mediated direct in vivo CRISPR screen identifies functional suppressors in glioblastoma*. Nat Neurosci, 2017. **20**(10): p. 1329-1341.
266. Chavez, A., et al., *Comparison of Cas9 activators in multiple species*. Nat Methods, 2016. **13**(7): p. 563-567.
267. Blakely, C.M., et al., *Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers*. Nat Genet, 2017. **49**(12): p. 1693-1704.
268. Morrissy, A.S., et al., *Divergent clonal selection dominates medulloblastoma at recurrence*. Nature, 2016. **529**(7586): p. 351-7.
269. Chapeau, E.A., et al., *Resistance mechanisms to TP53-MDM2 inhibition identified by in vivo piggyBac transposon mutagenesis screen in an Arf(-/-) mouse model*. Proc Natl Acad Sci U S A, 2017. **114**(12): p. 3151-3156.
270. Fan, P.D., et al., *YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics*. Proc Natl Acad Sci U S A, 2018. **115**(26): p. E6030-E6038.
271. Guo, Y., et al., *Comprehensive Ex Vivo Transposon Mutagenesis Identifies Genes That Promote Growth Factor Independence and Leukemogenesis*. Cancer Res, 2016. **76**(4): p. 773-86.
272. Molyneux, S.D., et al., *Human somatic cell mutagenesis creates genetically tractable sarcomas*. Nat Genet, 2014. **46**(9): p. 964-72.
273. Kodama, T., et al., *Transposon mutagenesis identifies genes and cellular processes driving epithelial-mesenchymal transition in hepatocellular carcinoma*. Proc Natl Acad Sci U S A, 2016. **113**(24): p. E3384-93.
274. Chen, H.J., et al., *A recellularized human colon model identifies cancer driver genes*. Nat Biotechnol, 2016. **34**(8): p. 845-51.
275. Uhm, J.H., et al., *Phase II evaluation of gefitinib in patients with newly diagnosed Grade 4 astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074*. Int J Radiat Oncol Biol Phys, 2011. **80**(2): p. 347-53.
276. Reardon, D.A., et al., *Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma*. Neuro Oncol, 2015. **17**(3): p. 430-9.
277. Reardon, D.A., et al., *A phase I/II trial of pazopanib in combination with lapatinib in adult patients with relapsed malignant glioma*. Clin Cancer Res, 2013. **19**(4): p. 900-8.
278. Lassman, A.B., et al., *Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01*. Clin Cancer Res, 2005. **11**(21): p. 7841-50.
279. Martens, T., et al., *Inhibition of glioblastoma growth in a highly invasive nude mouse model can be achieved by targeting epidermal growth factor receptor but not vascular endothelial growth factor receptor-2*. Clin Cancer Res, 2008. **14**(17): p. 5447-58.
280. Neyns, B., et al., *Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma*. Ann Oncol, 2009. **20**(9): p. 1596-603.
281. Hasselbalch, B., et al., *Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial*. Neuro Oncol, 2010. **12**(5): p. 508-16.
282. Talavera, A., et al., *Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation*. Cancer Res, 2009. **69**(14): p. 5851-9.

283. Westphal, M., et al., *A randomised, open label phase III trial with nimotuzumab, an anti-epidermal growth factor receptor monoclonal antibody in the treatment of newly diagnosed adult glioblastoma*. Eur J Cancer, 2015. **51**(4): p. 522-32.
284. Bode, U., et al., *Nimotuzumab treatment of malignant gliomas*. Expert Opin Biol Ther, 2012. **12**(12): p. 1649-59.
285. Lim, W.A. and C.H. June, *The Principles of Engineering Immune Cells to Treat Cancer*. Cell, 2017. **168**(4): p. 724-740.
286. Morgan, R.A., et al., *Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma*. Hum Gene Ther, 2012. **23**(10): p. 1043-53.
287. Swartz, A.M., Q.J. Li, and J.H. Sampson, *Rindopepimut: a promising immunotherapeutic for the treatment of glioblastoma multiforme*. Immunotherapy, 2014. **6**(6): p. 679-90.
288. Malkki, H., *Trial Watch: Glioblastoma vaccine therapy disappointment in Phase III trial*. Nat Rev Neurol, 2016. **12**(4): p. 190.
289. Wikstrand, C.J., et al., *The class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immunotherapeutic target*. J Neurovirol, 1998. **4**(2): p. 148-58.
290. Cho, J., et al., *Glioblastoma-derived epidermal growth factor receptor carboxyl-terminal deletion mutants are transforming and are sensitive to EGFR-directed therapies*. Cancer Res, 2011. **71**(24): p. 7587-96.
291. Patel, A.P., et al., *Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma*. Science, 2014. **344**(6190): p. 1396-401.
292. Snuderl, M., et al., *Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma*. Cancer Cell, 2011. **20**(6): p. 810-7.
293. Lee, J.K., et al., *Pharmacogenomic landscape of patient-derived tumor cells informs precision oncology therapy*. Nat Genet, 2018. **50**(10): p. 1399-1411.
294. Weller, M., et al., *Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups*. Acta Neuropathol, 2015. **129**(5): p. 679-93.
295. Sturm, D., et al., *New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs*. Cell, 2016. **164**(5): p. 1060-1072.
296. Guo, X.E., et al., *Targeting tumor suppressor networks for cancer therapeutics*. Curr Drug Targets, 2014. **15**(1): p. 2-16.
297. Issaeva, N., et al., *Small molecule RITA binds to p53, blocks p53-MDM2 interaction and activates p53 function in tumors*. Nat Med, 2004. **10**(12): p. 1321-8.
298. Lee, Y.R., M. Chen, and P.P. Pandolfi, *The functions and regulation of the PTEN tumour suppressor: new modes and prospects*. Nat Rev Mol Cell Biol, 2018. **19**(9): p. 547-562.